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ABSTRACT
Introduction: Lisdexamfetamine dimesylate
(LDX) is a long-acting prodrug stimulant for
the treatment of attention-deficit/hyperactivity
disorder (ADHD). Post hoc subgroup analyses
were performed from two studies in children
with ADHD to compare the efficacy of LDX
in participants who had received prior
methylphenidate (MPH) treatment with that
of the overall study populations.
Methods: Study 1 (7-week; open-label design)
and study 2 (randomized, double-blind, placebo-
controlled, crossover, laboratory school design)
enrolled children aged 6–12 years with ADHD
and baseline ADHD Rating Scale IV (ADHD-RS-
IV) total score C28. Both studies excluded
children whose prestudy ADHD treatment
provided effective control of ADHD symptoms
with an acceptable safety profile. Post hoc
efficacy analyses were performed in children
who had received MPH within 6 months of
study enrollment. Efficacy measures included
the following scales: ADHD-RS-IV, Clinical
Global Impressions-Improvement (CGI-I),
Expression and Emotion Scale for Children
(EESC), Behavior Rating Inventory of Executive
Function (BRIEF), Swanson, Kotkin, Agler,
M-Flynn, and Pelham (SKAMP), and Permanent
Product Measure of Performance (PERMP).
Results: In studies 1 and 2, 83/318 (26%) and
67/129 (52%) participants, respectively, had
received MPH within 6 months and were not
adequately controlled on current medication
with acceptable tolerability; most of these
participants had received long-acting MPH. In
prior MPH participants, efficacy assessments
demonstrated improvements from baseline
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(study 1) and versus placebo (study 2) that were
comparable with those seen in the respective
overall study population. Safety profiles were
consistent with long-acting stimulant use.
Conclusion: In two studies, children who had
received prior MPH treatment improved during
treatment with LDX and experienced similar
improvements in their symptoms as the overall
study populations. For children with ADHD who
were previously treated with MPH, LDX may,
therefore, be an efficacious treatment option.
Keywords: Attention-deficit/hyperactivity





is a common neurobehavioral disorder in
children [1]. As reviewed by Rader et al.,
stimulants have been used for decades to treat
ADHD symptoms [2, 3] and remain a first-line
option [2, 4]. Methylphenidate (MPH) and
amphetamine (AMP) psychostimulants have
similar subjective effects [5], but somewhat
different mechanisms of action [6–8].
The selection of an AMP- or MPH-based
medication as the first-choice treatment should
be left to the physician, in consultation with the
patient and family [9]. ADHD treatment
guidelines recommend that, if treatment with
one stimulant is ineffective, an alternative
stimulant should be attempted before
considering second-line therapy [2]. This is
supported by crossover trials which suggest that
the outcome of treatment with one stimulant is
not predictive of that with the other [10, 11].
However, a greater understanding of the response
to treatment in patients who have previously
received a different stimulant will further
assist prescribers in making informed clinical
choices.
Lisdexamfetamine dimesylate (LDX) is a
long-acting prodrug stimulant approved for
the treatment of ADHD in the United States
and Canada for children 6–12 years of age,
adolescents 13–17 years of age, and adults. In
Europe, LDX is indicated as part of a
comprehensive treatment program for ADHD
in children aged 6 years and over, when
response to previous MPH treatment is
considered clinically inadequate. After oral
ingestion, therapeutically inactive LDX is
converted to l-lysine and active d-AMP in the
blood [12]. LDX was designed to have an
extended duration, without the need for
multiple daily dosing [13, 14]. Clinical trials of
LDX have demonstrated short- and long-term
efficacy [13–17].
In a 7-week, open-label, dose-optimization
study (study 1) of children with ADHD [16],
LDX (20–70 mg/day) was effective, as assessed
by a clinician-rated symptom scale and by
clinician- and parent-rated global measures.
Since many children with ADHD also
experience impairments in executive function
(EF) [18] and in emotional function across
settings [19], this study measured these
impairments at baseline and posttreatment.
The Behavior Rating Inventory of Executive
Function (BRIEF) scale [20, 21] examined real-
world parent-assessed EF behaviors and the
Expression and Emotion Scale for Children
(EESC) [22] evaluated parent-rated negative/
positive aspects of emotional expression in
children before and during treatment.
Participants significantly improved versus
baseline in BRIEF and EESC total and subscale
scores following LDX treatment [16].
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Children with ADHD exhibit impairments in
the school setting, due to inattention and
hyperactivity/impulsivity; therefore, laboratory
school models have been used to assess ADHD
impact and treatments. A randomized, placebo-
controlled, crossover study (study 2) [14]
evaluated the impact of LDX treatment from
dosing to 13 h post-dose using a laboratory
school setting. The Swanson, Kotkin, Agler,
M-Flynn, and Pelham (SKAMP) scale, a
clinician-rated assessment of classroom
behavior with subscales for deportment
(SKAMP-D) and attention (SKAMP-A) [14, 23],
and the Permanent Product Measure of
Performance (PERMP), a series of skill-adjusted,
timed (10-min) math tests that measure ability to
attend to work and effortful performance [24],
were used. Children receiving LDX treatment
had significantly improved SKAMP and PERMP
scores at all time points versus placebo (1.5–13 h
post-dose) [14]. In studies 1 and 2, treatment-
emergent adverse events (TEAEs) were consistent
with other pediatric studies of LDX [14, 16].
Given the paucity of empirical evidence on
the response to stimulant medication in
patients who have previously received another
stimulant, the current post hoc analyses
examined the effects of LDX treatment in
subgroups of children who had taken MPH in
the 6-month period before enrollment in
studies 1 and 2, without knowledge of the
outcome of this prior therapy. All participants
in these two studies [14, 16] had at least
moderately symptomatic ADHD at baseline.
The study outcomes analyzed were clinician-
rated ADHD symptoms and global severity,
parent-rated EF behaviors and emotional
expression, and investigator-assessed behavior
and effortful performance. The results may help
clinicians determine whether LDX is an
appropriate option for patients who have
recently been exposed to MPH.
METHODS
These post hoc subanalyses examined the
efficacy measures from two multicenter studies
of the efficacy and safety of LDX conducted in
children with ADHD aged 6–12 years, herein
referred to as study 1 [16] and study 2 [14].
Study 1 was a prospective, 7-week, open-label
dose-optimization study; and study 2 was a
laboratory school study incorporating a 4-week
dose-optimization phase, followed by a 2-week,
randomized, double-blind, placebo-controlled,
crossover period. Both studies enrolled children
with a baseline ADHD Ratings Scale IV [25]
(ADHD-RS-IV) total score C28, but excluded
patients whose pre-study ADHD treatment
provided effective control of ADHD symptoms
with acceptable tolerability, and patients who
had failed to respond to a course of AMP
therapy of adequate dose and duration.
The subgroups for the present analyses
comprised children who had been treated
with MPH (MPH hydrochloride, MPH, or
dexmethylphenidate hydrochloride) at any
time within the 6-month period immediately
prior to study enrollment. If on treatment at
screening, participants underwent a washout
period of at least 7 days prior to baseline.
Study 1
Study 1 evaluated LDX (20–70 mg/day) efficacy
in children (6–12 years) with ADHD with
baseline ADHD-RS-IV total score C28 and was
described in full previously [16]. The primary
efficacy assessment was the change in ADHD-
RS-IV total score from baseline to endpoint.
Secondary efficacy measures included the
Clinical Global Impressions (CGI) scale [26],
the EESC [22], and the BRIEF-Parent Form [20].
ADHD-RS-IV is an 18-item, clinician-rated
scale based on criteria of the Diagnostic and
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Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR), with
symptoms grouped into two subscales
(inattention and hyperactivity/impulsivity)
[25, 27]. Each symptom item was scored from
0 (never or rarely) to 3 (very often); total scores
ranged from 0 to 54. The CGI global
assessments evaluated baseline severity and
improvement over time. At baseline, the CGI-
Severity (CGI-S) scale rated ADHD severity from
1 (normal/not at all ill) to 7 (among the most
extremely ill). At all subsequent visits, the CGI-
Improvement (CGI-I) assessed improvement
from 1 (very much improved) to 7 (very much
worse). The EESC is a 29-item validated measure
of emotional expression; total scores ranged
from 29 to 145, higher scores indicating greater
impairment [22]. The EESC was administered at
baseline and at the final study week. The BRIEF-
Parent Form is an 86-item validated assessment
of EF in children (5–18 years) [20, 21]. Global
Executive Composite (GEC) scores were
transformed to T-scores. T-scores of 50
represent the mean for the normative group
distribution [20]. T-scores C65 [C1.5 standard
deviation (SD) above the mean] on BRIEF
clinical scales and indices were considered
potentially clinically significant scores.
Study 2
Study 2, in children (6–12 years) with ADHD
and a baseline ADHD-RS-IV score C28,
evaluated LDX (30–70 mg/day) efficacy and
was described in full previously [14]. Study 2
included a 4-week, open-label, dose-
optimization phase, followed by a crossover
phase where each participant took LDX and
placebo for 1 week each in randomized order.
The primary efficacy measure was the mean
SKAMP-D subscore over the course of a
laboratory school day. Secondary efficacy
measures included SKAMP-A, PERMP math
scores, ADHD-RS-IV, and CGI scores. All
efficacy assessments reported here are for the
crossover phase.
The SKAMP scale [23] is a 13-item validated
rating scale used to evaluate ADHD
manifestations in a laboratory school setting.
In addition to a total score, subscores are
calculated for deportment and attention [14,
23]. PERMP consists of a 5-page, 80-problem
math test, and participants are scored according
to the number of problems attempted and the
number solved correctly in a 10-min period
[24]. SKAMP and PERMP assessments were made
0.5 h pre-dose and 1.5–13.0 h post-dose. ADHD-
RS-IV and CGI scores were measured at baseline
and at all subsequent weeks, including the two
crossover weeks (visits 5/6).
Studies 1 and 2 Analyses
Efficacy outcomes for the overall group were
analyzed according to the efficacy population,
defined as all randomized participants who
received C1 dose of study treatment with C1
available post-randomization measure of the
primary efficacy variable. Efficacy outcomes for
the study 1 post hoc analysis were for all LDX
dose groups combined from baseline to
endpoint, defined as the last valid efficacy
assessment (i.e., ADHD-RS-IV) post-baseline.
For study 2, efficacy outcomes were reported
from baseline to weeks 5 and 6 (visit 5/6), the
two crossover phase assessments, for
participants taking LDX (all doses) and placebo.
Clinical Response Criteria
A child may exhibit considerable clinical
response to treatment from baseline, using the
ADHD-RS-IV scale, yet still be symptomatic.
Inclusion of the CGI-I criteria may clinically
define how well a participant improved with
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treatment from baseline, although this child
still exhibited ADHD symptoms. A stringent
definition for clinical response that combines
the two criteria may provide more insight into
treatment options for clinicians [28]. For this
analysis, clinical responders were classified as
participants who achieved at least a 30%
reduction in ADHD-RS-IV total score from
baseline and a CGI-I score of 1 or 2.
Symptomatic Remission Criteria
There are varying definitions of thresholds to
describe ADHD symptomatic remission, which
may include clinical response to a degree that
the participant no longer exhibits symptoms
sufficient to meet DSM-IV-TR criteria [29]. Here,
the authors used a conservative definition of
symptomatic remission with no symptom item
on the ADHD-RS-IV endorsed as more severe
than mild [28]. Thus, symptomatic remission
was defined as ADHD-RS-IV item scores of B1,
for each of the 18 items, at endpoint in study 1
or during the crossover phase of study 2.
Symptomatic remission, as defined in this
analysis, may be considered a more stringent
definition than that defined in prior LDX
studies and analyses (ADHD-RS-IV total score
of B18 at endpoint) [30–32]. An overall score of
B18 does not give specific information on the
effects of treatment on each individual item,
where the participant may still exhibit
symptom severity greater than mild on some
items.
Written informed consent was obtained
from each patient’s legal guardian, and assent
was obtained from each child prior to study-
related procedures being performed. The study
protocol was approved by the institutional
review board at each study center, and the
studies were performed in accordance with the
International Conference on Harmonisation of
Good Clinical Practice, 18th World Medical
Assembly (Helsinki 1964), and amendments of
the 29th (Tokyo 1975), the 35th (Venice 1983),
the 41st (Hong Kong 1989), and the 48th (South
Africa 1996) World Medical Assemblies.
RESULTS
Study 1
Baseline characteristics and demographics of
the overall study population have been
previously presented [16]. Of 318 enrolled
participants, 83 (26.1%) had taken MPH
within 6 months of study initiation, 67/83
(80.7%) were treated with long-acting MPH,
and 18/83 took C1 mg/kg/day (a dose
considered ‘‘generally effective’’ [33, 34].
Table 1 shows summary statistics for the
dosage and duration of this previous MPH
treatment. Children in the prior MPH group
had a mean age (SD) of 9.2 (1.88) years, a mean
(SD) weight of 33.6 (8.58) kg, and the majority
were male (65 of 83, 78.3%), similar to the
overall study population. The mean (SD)
ADHD-RS-IV baseline total score in this
subgroup was 42.6 (6.81) and was similar for
males and females with mean (SD) ADHD-RS-IV
total scores of 43.0 (6.94) and 41.3 (6.34),
respectively.
The mean (SD) change from baseline to
endpoint with LDX treatment for ADHD-RS-IV
total score was similar for the overall study
population and the prior MPH group (Fig. 1).
The mean (SD) relative improvement from
baseline to endpoint in ADHD-RS-IV total
score for children in the prior MPH group was
64.9% (23.88). Improvement with LDX was
numerically greater for males versus females;
the relative improvement was 66.3% (23.02)
with an endpoint ADHD-RS-IV total score of
14.1 (9.08) for males versus 59.7% (26.80) with
an endpoint ADHD-RS-IV total score of 16.6
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(11.69) for females. At endpoint, inattention
and hyperactivity/impulsivity subscale scores
for prior MPH participants were improved
overall by 62.7% (26.97) and 67.2% (24.39)
from baseline, respectively.
Other secondary efficacy assessments also
demonstrated improvement with LDX. Mean
(SD) BRIEF GEC scores at baseline and endpoint
were similar for the overall study population
and prior MPH group (Fig. 2). Mean (SD) CGI-I
scores at endpoint, and EESC total scores, and
BRIEF index subscale scores (Behavioral
Recognition Index and Metacognition Index)
at baseline and endpoint, were similar between
the overall study population and prior MPH
group (Table 2). Moreover, with LDX treatment
the BRIEF index subscale scores were
normalized at endpoint (Fig. 2; Table 2).
Rates of symptomatic remission in the
overall study population (49.1%) and prior
MPH group (42.2%) were similar at endpoint
of study 1, although the prior MPH group had
numerically lower symptomatic remission rates
compared with the overall group, including the
subgroups of prior MPH participants with MPH
doses \1 or C1 mg/kg/day (Fig. 3). Moreover,
283 of 316 (89.6%) participants in the overall
study population and 72 of 83 (86.7%) prior
MPH participants at endpoint achieved clinical
response (C30% reduction from baseline in
ADHD-RS-IV total score and CGI-I rating of 1
or 2) with LDX.
Study 2
Baseline characteristics and demographics of
the overall study population have been
previously presented [14]. Of the 129 enrolled
participants, 67 (51.9%) had taken MPH within
6 months prior to study entry; all but two were
treated with long-acting MPH and 17/67 took
C1 mg/kg/day. Table 3 shows summary
statistics for the dosage and duration of this
previous MPH treatment. In the crossover
Table 1 Prior methylphenidate (MPH) dosage summary
statistics for Study 1 (n = 83)




357.9 (505.36) 202.0 (1–3.060)
MPH dose, mg/day 24.6 (20.35) 20.0 (0–144)
MPH dose, mg/kg/
day
0.8 (0.63) 0.6 (0–4)
Fig. 1 Study 1 ADHD-RS-IV total scores for overall study population and prior MPH group. ADHD-RS-IV Attention-
Deﬁcit/Hyperactivity Disorder Rating Scale IV, MPH methylphenidate, SD standard deviation
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phase, 113 children including all 67 prior MPH
participants were included in the overall study
population. Children in the prior MPH group
had a mean age (SD) of 10.0 (1.60) years, a mean
(SD) weight of 31.6 (6.98) kg, and the majority
were male (54 of 67, 80.6%), similar to the
overall study population. The mean (SD)
ADHD-RS-IV baseline total score in this
subgroup was 43.1 (7.22) and was similar for
males and females with mean (SD) ADHD-RS-IV
total scores of 42.6 (7.27) and 45.2 (6.87),
respectively.
Change from baseline in mean (SD) ADHD-
RS-IV total scores for participants when taking
LDX and placebo during the crossover phase
were similar for the overall study population
(n = 113) and prior MPH group (n = 67) (Fig. 4).
The mean (SD) relative improvement from
baseline to endpoint in ADHD-RS-IV total
score for children who had previously received
MPH was 57.1% (26.11) in the LDX treatment
group and 18.1% (28.85) in the placebo group.
For prior MPH participants who had received
average MPH dose C1 mg/kg/day (n = 17), from
Fig. 2 Study 1 BRIEF GEC T-scores for overall study population and prior MPH group. BRIEF Behavior Rating
Inventory of Executive Function, GEC Global Executive Composite, MPH methylphenidate, SD standard deviation
Table 2 Study 1: CGI-I, EESC, and BRIEF index subscales for the overall study population and prior methylphenidate
(MPH) group
Overall study population Prior MPH group
Baseline Endpoint Baseline Endpoint
CGI-I – 1.5 (0.8) – 1.6 (0.8)
EESC 63.4 (18.0) 55.9 (17.7) 63.3 (17.1) 55.4 (17.3)
BRIEF indexes
Behavioral regulation index 71.0 (11.8) 55.7 (12.5) 71.6 (11.4) 57.9 (12.3)
Metacognition index 73.1 (8.4) 55.5 (11.5) 71.6 (9.7) 57.7 (11.6)
CGI-I Clinical Global Impressions-Improvement, BRIEF Behavior Rating Inventory of Executive Function, EESC
Expression and Emotion Scale for Children
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a mean (SD) baseline score of 43.6 (7.71), the
mean (SD) relative improvement in ADHD-RS-
IV total scores was 58.0% (21.16) with LDX and
16.4% (25.58) with placebo.
ForpriorMPHmales, fromamean(SD)baseline
score of 42.6 (7.27), the mean (SD) relative
improvement in ADHD-RS-IV total scores was
55.3% (27.07) with LDX and 17.6% (29.38) with
placebo; for prior MPH females, from a mean (SD)
baseline scoreof45.2 (6.87), themean(SD) relative
improvement in ADHD-RS-IV total scores was
64.8% (20.79) with LDX and 19.9% (27.59) with
placebo. Least squares (LS) mean [95% confidence
interval (CI)] difference (LDX minus placebo)
was -17.1 (-20.41, -13.78; P\0.0001) and
-17.1 (-21.38, -12.85) for the overall study
population and prior MPH participants,
respectively. The overall LS [standard error (SE)]
Fig. 3 Study 1 rates of symptomatic remission* for overall
study population and prior MPH group. ADHD-RS-IV
Attention-Deﬁcit/Hyperactivity Disorder Rating Scale IV,
MPH methylphenidate. *Symptomatic remission deﬁned as
all ADHD-RS-IV item scores B1
Table 3 Prior methylphenidate (MPH) dosage summary
statistics for Study 2 (n = 67)




458.1 (455.57) 323.0 (4–2,335)
MPH dose, mg/day 27.1 (15.10) 24.0 (0–90)
MPH dose, mg/kg/
day
0.9 (0.54) 0.8 (0–3)
Fig. 4 Study 2 ADHD-RS-IV total scores for overall study
population and prior MPH group. ADHD-RS-IV Atten-
tion-Deﬁcit/Hyperactivity Disorder Rating Scale IV, LDX
lisdexamfetamine dimesylate, MPH methylphenidate, SD
standard deviation
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effect size of LDX was -1.4 (0.16) and -1.4 (0.21)
for the overall study population and prior MPH
participants, respectively.
For prior MPH participants, mean (SD) relative
improvement in ADHD-RS-IV inattention
subscale scores was 56.3% (27.54) with LDX and
17.0% (28.61) with placebo from a mean (SD)
baseline score of 21.4 (4.14). The mean
(SD) relative improvement in ADHD-RS-IV
hyperactivity/impulsivity subscale scores was
57.9% (28.22) with LDX and 18.2% (33.14) with
placebo from a mean (SD) baseline score of 21.7
(4.32).
Improvements in SKAMP-D were similar in
the overall study population and prior MPH
participants. For both, SKAMP-D scores were
improved at all post-dose time points from 1.5
to 13 h with LDX versus placebo (P B 0.0046
and P B 0.0284 for all time points in the
overall study population and prior MPH
group, respectively) (Fig. 5a). LS mean
(95% CI) difference was -0.74 (-0.85, -0.63;
P\0.0001) and -0.83 (-1.03, -0.64;
P\0.0001) for the overall study population
and prior MPH participants, respectively. The
overall LS (SE) effect size of LDX was -1.73
(0.18) and -1.77 (0.28) for the overall study
population and prior MPH participants,
respectively. Similarly for SKAMP-A,
improvements with LDX were similar in the
overall study population and prior MPH
participants improvements seen from 1.5 h, up
to and including 13 h post-dose with LDX
versus placebo (P\0.0001 and P B 0.0114 for
all time points in the overall study population
and prior MPH group, respectively) (Fig. 5b). LS
mean (95% CI) difference (LDX minus placebo)
was -0.78 (-0.87, -0.70; P\0.0001) and -0.6
(-0.76, -0.44; P\0.0001) for the overall study
population and prior MPH participants,
respectively. The overall LS (SE) effect size of
LDX was -2.41 (0.21) and -1.6 (0.27) for the
overall study population and prior MPH
participants, respectively.
Both the overall study population and the
prior MPH groups performed similarly on the
PERMP (Fig. 5c, d). PERMP-A and PERMP-C
scores were improved at all post-dose time
points from 1.5 to 13 h with LDX versus
placebo (P\0.0001 for all time points in the
overall study population and prior MPH
participants, respectively, for both PERMP-A
and PERMP-C).
At visit 5/6 of the crossover period, mean
(SD) CGI-I scores for participants taking LDX
and placebo, respectively, were 1.7 (0.9) and 3.5
(1.2) for the overall study population, 1.7 (0.96)
and 3.6 (1.14) for prior MPH participants, and
1.7 (0.85) and 3.7 (0.99) for prior MPH
participants who had received C1 mg/kg/day
MPH.
At visit 5/6 of the crossover phase, 54 of 67
(80.6%) achieved clinical response with LDX
and 10 of 67 (14.9%) participants with placebo.
Rates of symptomatic remission were similar in
the overall study population (LDX 31.9%,
placebo 9.7%) and the prior MPH group (LDX
28.4%, placebo 10.4%), including the
subgroups of prior MPH participants with
MPH doses \1 or C1 mg/kg/day (Fig. 6).
Summary of Safety Findings in Study 1
and Study 2
Safety data from both studies have been
previously reported [14, 16] and are briefly
summarized here for reference. In study 1, the
majority of treated participants [269/317
(84.9%)] experienced TEAEs with LDX. TEAEs
reported by C10% of participants included
decreased appetite (43.2%), decreased weight
(17.0%), insomnia (16.1%), irritability (16.1%),
headache (13.9%), upper abdominal pain
(13.2%), and initial insomnia (11.4%); the
480 Adv Ther (2013) 30:472–486
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majority were mild to moderate in severity.
There were no deaths; two serious AEs (i.e.,
syncope, sinus arrest) were reported [16]. In
study 2, the majority of participants [110/129
(85.3%)] experienced TEAEs with LDX during
the open-label phase. TEAEs reported by C10%
of participants included decreased appetite
(47.3%), insomnia (27.1%), headache (17.1%),
irritability (16.3%), upper abdominal pain
(15.5%), and affect lability (10.1%); the
majority were mild or moderate in intensity
[14]. There were no deaths or serious AEs. In
both studies, small increases in blood pressure
and pulse were observed consistent with AMP
treatment, and there were no clinically
meaningful trends observed in
electrocardiogram (ECG) interval data [14, 16].
DISCUSSION
The present analyses did not specifically
identify patients whose previous MPH
treatment had failed, but did comprise
patients who had received any prior MPH
treatment within 6 months, and were not
excluded on the grounds of adequate
symptomatic control and acceptable
tolerability with current medication. In studies
1 and 2 [14, 16], LDX effectively reduced ADHD
symptoms in children previously treated with
MPH within 6 months of study initiation, most
of whom were previously treated with long-
acting MPH. For prior MPH participants, ADHD-
RS-IV total scores decreased at endpoint by a
mean of 64.9% in study 1. At the end of the
crossover phase of study 2, mean ADHD-RS-IV
total scores were lower for prior MPH
participants receiving LDX (57.1% reduction)
and placebo (18.1% reduction). The results were
comparable with the overall populations for
both studies; however, a trend that suggests a
slightly lower reduction in ADHD-RS-IV scores
Fig. 5 Study 2 LS Mean (SE) SKAMP-D (a), SKAMP-A
(b), PERMP-A (c), and PERMP-C (d) scores for overall study
population and prior MPH group. LDX lisdexamfetamine
dimesylate, MPH methylphenidate, PERMP Permanent
Product Measure of Performance Attempted (PERMP-A)
and Correct (PERMP C), SE standard error, SKAMP
Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment
(SKAMP-D) and Attention (SKAMP-A) scale
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with LDX in the prior MPH group versus the
respective overall study populations exists. CGI-
I results confirm the efficacy of LDX in prior
MPH participants. In study 1, the mean CGI-I
for prior MPH participants at endpoint was 1.6.
At the end of the crossover phase of study 2, the
mean CGI-I for prior MPH participants
receiving LDX was 1.7 versus 3.6 when
receiving placebo. These values are comparable
to those of the overall study populations of
study 1 (1.5) and study 2 (1.7 LDX, 3.5 placebo).
In study 2, LDX demonstrated efficacy versus
placebo in children with prior MPH treatment by
improving attention, behavior, and math scores
as assessed with SKAMP-A, SKAMP-D, and PERMP
scores, respectively. This effect was sustained
from 1.5 to 13.0 h post-dose (last time point
assessed) for SKAMP-A, SKAMP-D, and PERMP
scores. Overall, the results of these analyses are in
line with a similar post hoc analysis of data from
a 4-week, parallel-group, placebo-controlled
study of LDX efficacy in children with ADHD
that found improvements in ADHD symptoms
and global illness were comparable between prior
MPH users and the overall study population [32].
Clinical trials of ADHD generally focus on core
ADHD symptom of inattention and
hyperactivity/impulsivity. Nevertheless, ADHD
is associated with impairment in EF, as reviewed
by Edward Brown, which is considered by many
as an essential component of ADHD etiology
[35]. Study 1 examined BRIEF scores as a measure
of EF. LDX treatment resulted in improvements
in BRIEF scores among prior MPH children,
indicating that parents perceived improved EF
in daily life. The magnitude of the improvement
seen in BRIEF GEC score in this post hoc analysis
is comparable to that in the overall study
population. All BRIEF subscale scores were
normalized with LDX treatment. For example,
improved BRIEF subscale score for emotional
control may demonstrate improvements in the
child’s ability to better manage emotional
responses and, therefore, core EF behaviors such
as emotional regulation and frustration
modulation [18, 20, 21].
The EESC results from study 1 suggest that
LDX treatment in prior MPH children with
ADHD does not negatively affect overall
emotional expression. Children with ADHD
have significantly worse scores on measures of
emotional well-being than children without
ADHD [19]. Although this has not been
established in clinical trials, emotional
Fig. 6 Rates of symptomatic remission* for the overall
study population and the prior MPH groups. ADHD-RS-
IV Attention-Deﬁcit/Hyperactivity Disorder Rating Scale
IV, MPH methylphenidate. *Symptomatic remission
deﬁned as all ADHD-RS-IV item scores B1
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flattening resulting from stimulants is a concern
of clinicians and parents [22]. The magnitude of
improvement in the EESC total score for prior
MPH children in this analysis was comparable
to the overall study.
Differential clinical response rates to
stimulant treatment are common [10, 11]. Due
to suboptimal treatment of ADHD, alternative
stimulants should be evaluated to improve
patient outcomes [2]. Clinical response rate
can be improved to an estimated 92% when
stimulants are tried sequentially, after one has
failed [10]. There has been limited systematic
evaluation of patient outcomes after switching
stimulants. The authors’ findings suggest that
LDX may provide effective symptom control in
children with ADHD who have had prior MPH
exposure. A substantial proportion of
participants in both studies achieved
symptomatic remission, suggesting that LDX
treatment in children previously treated with
MPH had improved ADHD symptoms. Based on
the study data, many patients previously treated
with MPH may respond well to LDX and
achieve symptomatic remission, although
overall remission rates may be slightly lower
in prior MPH-treated patients. These results
agree with those of a recent post hoc analysis
which found that children with significant
ADHD symptoms despite MPH treatment
improved on LDX to a similar degree to the
overall study population [32].
Both studies were not prospectively designed to
examine the effects of LDX on MPH
nonresponders; hence, the interpretation of the
findings from this manuscript was confounded by
the post hoc nature of the analyses. Study 1 was
limited by the lack of a placebo group for
comparison. In contrast, study 2 was
strengthened by the utilization of the placebo-
controlled laboratory school setting and the
blinded design of the crossover phase. The dose-
optimization phase of both studies allowed
assessment of participants at optimal doses,
closely approximating clinical practice in
medication dosing. Another limitation was that
participants were not necessarily taking MPH
immediately before screening (only had taken
MPH within 6 months of study), which limits
extrapolation of these findings. There were no
comparable reports of symptom control on prior
MPH using the ADHD-RS-IV or other study
measures, and often precise dates for initiation/
termination of prior treatment were missing. Nor
was there control over patient compliance/
adherence to the prior MPH regimen. Since
participants who were responding well to, and
tolerating, their prior medication were excluded
from both studies of the overall study populations,
it is presumed that enrolled participants were
those who may have discontinued MPH therapy
due to poor efficacy or tolerability.
CONCLUSION
For children with ADHD who were previously
treated with MPH, LDX may be an efficacious
treatment option, by significantly reducing
ADHD symptoms, improving EF and
emotional expression as well as attention and
deportment in the laboratory school setting.
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